|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
WO2014096965A2
(en)
|
2012-12-21 |
2014-06-26 |
Rvx Therapeutics Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
MX366703B
(es)
|
2013-03-15 |
2019-07-22 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de la proteína bet.
|
|
CA2901083A1
(en)
|
2013-04-26 |
2014-10-30 |
Beigene, Ltd. |
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
WO2015004533A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
SG11201510409QA
(en)
|
2013-06-21 |
2016-01-28 |
Zenith Epigenetics Corp |
Novel bicyclic bromodomain inhibitors
|
|
WO2015006193A1
(en)
|
2013-07-08 |
2015-01-15 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
WO2015015318A2
(en)
|
2013-07-31 |
2015-02-05 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
UA119870C2
(uk)
|
2014-04-23 |
2019-08-27 |
Інсайт Корпорейшн |
1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
|
|
US9902702B2
(en)
*
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
|
DK3212789T3
(da)
|
2014-10-31 |
2020-07-27 |
Massachusetts Inst Technology |
Massiv parallel kombinatorisk genetik til crispr
|
|
US10710992B2
(en)
|
2014-12-01 |
2020-07-14 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
EP3227280B1
(en)
*
|
2014-12-01 |
2019-04-24 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
JP2017537946A
(ja)
|
2014-12-11 |
2017-12-21 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての置換複素環
|
|
HK1245247A1
(zh)
|
2014-12-17 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
CA2988209A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Orion Corporation |
Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
TW201722966A
(zh)
|
2015-10-29 |
2017-07-01 |
英塞特公司 |
Bet蛋白質抑制劑之非晶固體形式
|
|
AU2017281286B2
(en)
|
2016-06-20 |
2021-05-20 |
Incyte Corporation |
Crystalline solid forms of a bet inhibitor
|
|
WO2018109271A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
CN107739370B
(zh)
*
|
2017-10-26 |
2021-03-30 |
中国药科大学 |
吡咯酮类brd4蛋白抑制剂的制备方法以及用途
|
|
CN109928979B
(zh)
*
|
2017-12-15 |
2021-08-06 |
四川科伦博泰生物医药股份有限公司 |
吲哚酮类衍生物及其制备方法和用途
|
|
CN108383771A
(zh)
*
|
2018-01-08 |
2018-08-10 |
华东师范大学 |
手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
|
|
ES3053198T3
(en)
*
|
2018-08-27 |
2026-01-20 |
Arcus Biosciences Inc |
Cd73 inhibitors
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
CN113710668B
(zh)
*
|
2019-04-09 |
2025-01-07 |
Opna生物公司 |
用于ep300或cbp调节及其适应症的缩合吖嗪
|
|
WO2021065980A1
(ja)
|
2019-09-30 |
2021-04-08 |
協和キリン株式会社 |
Ｂｅｔ分解剤
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
EP3912625A1
(en)
|
2020-05-20 |
2021-11-24 |
Kaerus Bioscience Limited |
Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
EP4580618A2
(en)
*
|
2022-08-30 |
2025-07-09 |
Pannex Therapeutics Inc. |
Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated
|
|
WO2025233532A1
(en)
|
2024-05-10 |
2025-11-13 |
Les Laboratoires Servier |
Maxi-k potassium channel openers and therapeutic applications thereof
|